PharmaEngine

PharmaEngine FCF per Share

The Free Cash Flow per Share of PharmaEngine (4162.TWO) as of Nov 12, 2026 is 12.19 TWD. In the previous year, Free Cash Flow per Share was 3.17 TWD — a change of 284.61% (higher).

FCF per Share

12.19TWD

YoY

284.61%

Last updated:

Free Cash Flow per Share of PharmaEngine is 2025 12.19 TWD. Free Cash Flow per Share of PharmaEngine was 2024 3.17 TWD. It decreases by 284.61% higher compared to the previous year.

The PharmaEngine FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
5.02 TWD
Jan 1, 2019
0.11 TWD
Jan 1, 2020
0.45 TWD
Jan 1, 2021
6.48 TWD
Jan 1, 2022
1.38 TWD
Jan 1, 2023
1.78 TWD
Jan 1, 2024
3.17 TWD
Jan 1, 2025
12.19 TWD
The PharmaEngine FCF per Share history
YEARFCF per ShareYoY
12.19TWD+284.61%
3.17TWD+77.77%
1.78TWD+29.34%
1.38TWD-78.73%
6.48TWD+1,328.32%
0.45TWD+322.94%
0.11TWD-97.86%
5.02TWD-362.87%
-1.91TWD-132.14%
5.94TWD+100.31%
2.96TWD+226.60%
0.91TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus. PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

Free Cash Flow per Share of PharmaEngine is 12.19 TWD in 2025.

Free Cash Flow per Share of PharmaEngine changed from 3.17 TWD to 12.19 TWD, representing a 284.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share PharmaEngine since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — PharmaEngine

All Key Metrics — PharmaEngine